Ultragenyx Pharmaceutical Inc (RARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$17.16+3.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RARE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -72.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 31.2% |
Growth built into the price is above our model estimate.
The price assumes 103.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
RARE — earnings miss
Dated 2026-11-03
Results of Operations and Financial Condition. On November 3, 2026, the Company issued a press release announcing its financial results for the three months ended September 30, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under
Why it matters: Both therapies won FDA approval in 2026. The company said it was ready to launch them, but its 2026 sales goal excludes new launches.
Supportive ifThe company reports first U.S. sales of both DTX401 and UX111, with no launch delay disclosed.
Worry ifEither launch is delayed, or the company reports no first sales in its next results update.
Why it matters: The company remains loss-making. It aims to cut 2027 research and sales costs by at least 15% from 2025.
Worry ifQ3 results show 2026 research and sales costs flat to down from 2025, with the 2027 cut of at least 15% intact.
Less concerning ifThe company raises its 2026 cost outlook or lowers the planned 2027 cut below 15%.
Why it matters: Dojolvi sales rose from $18M in Q1 to $27M in Q2. Japan sales began in May, and 2026 guidance is $100M–$110M.
Watch forDojolvi reaches at least $100M in 2026 sales, with Japan launch sales included.
Also watch forThe company cuts its Dojolvi range below $100M or reports a setback to Japan sales.
Why it matters: The settlement ends one patent case tied to DOJOLVI. The entry terms can show when a competing generic may reach the market.
Worry ifThe deal sets a DOJOLVI generic entry date before the listed patents expire.
Less concerning ifThe disclosed deal bars generic entry until the listed patents expire. It allows no earlier entry.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $473 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,475 loss on $10,000 · 64.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Q3 results test the 2026 revenue goal. The company reported $350M in first-half revenue and kept its full-year range.
Watch forQ3 results and updated guidance keep full-year 2026 revenue at $730M or higher.
Also watch forThe company cuts its 2026 revenue range below $730M, or Q3 results make that floor unattainable.